Related Experiment Videos
[Cyclophosphamide during pregnancy: a safe prescription]
R Nguyen Tan Lung1, M Granier, C Gaudry
1Département Mère-Enfant, CHG Louise-Michel, Quartier du Canal, Evry.
Summary
Cyclophosphamide use in pregnancy for severe glomerulonephritis is rare but can be safe. A case study shows a healthy infant born after maternal cyclophosphamide treatment for Henoch-Schönlein purpura.
Area of Science:
- Nephrology
- Rheumatology
- Teratology
Background:
- Cyclophosphamide, an alkylating agent, is a treatment for hematologic malignancies and progressive glomerulonephritis.
- Its use during pregnancy is infrequent due to potential teratogenic risks.
- Henoch-Schönlein purpura (HSP) is a systemic vasculitis that can affect the kidneys.
Observation:
- A case of HSP diagnosed in the first trimester of pregnancy is presented.
- Despite initial steroid treatment, the patient's glomerulonephritis progressed.
- Cyclophosphamide was administered from the 28th week of gestation until delivery.
Findings:
- The infant was born prematurely but exhibited no hematologic disorders or congenital malformations.
- Previous reports of malformations after in utero cyclophosphamide exposure involved concurrent teratogenic agents like radiotherapy or other chemotherapy drugs.
- This case suggests a potentially lower risk of teratogenicity when cyclophosphamide is used as a sole agent.
Implications:
- Cyclophosphamide may be a viable treatment option for severe, life-threatening maternal conditions during pregnancy when other options are insufficient.
- Careful risk-benefit assessment is crucial when considering cyclophosphamide in pregnant patients.
- Further research is warranted to fully elucidate the safety profile of cyclophosphamide monotherapy during pregnancy.